OSU-6162
OSU-6162
OSU-6162 (pronounced: O-S-U-Six-One-Six-Two), also known as PNU-96391A, is a psychoactive drug and research chemical of the aminotetralin chemical class. It acts as a weak dopamine D2 receptor antagonist or partial agonist, and has been researched for potential use in the treatment of schizophrenia and Parkinson's disease.
Etymology
The name OSU-6162 is derived from the initials of the Ohio State University (OSU), where the compound was first synthesized, and the unique identifier '6162' assigned to it during the research process. The alternative name PNU-96391A is a product code assigned by the pharmaceutical company Pfizer.
Pharmacology
OSU-6162 acts as a weak dopamine D2 receptor antagonist or partial agonist. This means it can either block or partially stimulate the dopamine D2 receptors in the brain. This mechanism of action is similar to that of many antipsychotic drugs, which is why OSU-6162 has been researched for potential use in the treatment of schizophrenia.
In addition to its effects on dopamine receptors, OSU-6162 may also have effects on other neurotransmitter systems. For example, it has been found to increase the release of acetylcholine in the brain, which could potentially contribute to its therapeutic effects.
Clinical Trials
OSU-6162 has been tested in several clinical trials for its potential use in the treatment of schizophrenia and Parkinson's disease. While the results of these trials have been promising, further research is needed to fully understand the drug's efficacy and safety profile.
Related Terms
External links
- Medical encyclopedia article on OSU-6162
- Wikipedia's article - OSU-6162
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski